Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free FAB Stock Alerts

Fusion Antibodies (FAB) Competitors

Fusion Antibodies logo
GBX 10.80 -0.20 (-1.82%)
As of 07/14/2026 11:37 AM Eastern
Compare

FAB vs. HEMO, ETX, POLB, HVO, and COIL

Should you buy Fusion Antibodies stock or one of its competitors? MarketBeat compares Fusion Antibodies with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Fusion Antibodies include Hemogenyx Pharmaceuticals (HEMO), e-therapeutics (ETX), Poolbeg Pharma (POLB), hVIVO (HVO), and Roquefort Therapeutics (COIL). These companies are all part of the "biotechnology" industry.

How does Fusion Antibodies compare to Hemogenyx Pharmaceuticals?

Fusion Antibodies (LON:FAB) and Hemogenyx Pharmaceuticals (LON:HEMO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their media sentiment, risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation.

Fusion Antibodies has a beta of 1.224, suggesting that its stock price is 22% more volatile than the broader market. Comparatively, Hemogenyx Pharmaceuticals has a beta of 1.53, suggesting that its stock price is 53% more volatile than the broader market.

Hemogenyx Pharmaceuticals has lower revenue, but higher earnings than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Hemogenyx Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A
Hemogenyx PharmaceuticalsN/AN/A-£6.89K-£170.60N/A

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 0.1% of Hemogenyx Pharmaceuticals shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by company insiders. Comparatively, 10.0% of Hemogenyx Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Hemogenyx Pharmaceuticals has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Fusion Antibodies' return on equity of -210.32% beat Hemogenyx Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Hemogenyx Pharmaceuticals N/A -2,807.75%-37.79%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled Hemogenyx Pharmaceuticals'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
Hemogenyx Pharmaceuticals Neutral

Summary

Hemogenyx Pharmaceuticals beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to e-therapeutics?

Fusion Antibodies (LON:FAB) and e-therapeutics (LON:ETX) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, valuation, earnings, risk and dividends.

e-therapeutics has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. e-therapeutics' return on equity of -38.75% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
e-therapeutics N/A -38.75%-29.10%

In the previous week, Fusion Antibodies' average media sentiment score of 0.00 equaled e-therapeutics'average media sentiment score.

Company Overall Sentiment
Fusion Antibodies Neutral
e-therapeutics Neutral

Fusion Antibodies has a beta of 1.224, indicating that its stock price is 22% more volatile than the broader market. Comparatively, e-therapeutics has a beta of 0.46, indicating that its stock price is 54% less volatile than the broader market.

Fusion Antibodies has higher revenue and earnings than e-therapeutics. Fusion Antibodies is trading at a lower price-to-earnings ratio than e-therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A
e-therapeutics£295K0.00-£10.06M-£0.02N/A

7.6% of Fusion Antibodies shares are held by institutional investors. Comparatively, 26.5% of e-therapeutics shares are held by institutional investors. 5.9% of Fusion Antibodies shares are held by insiders. Comparatively, 59.4% of e-therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Summary

e-therapeutics beats Fusion Antibodies on 6 of the 10 factors compared between the two stocks.

How does Fusion Antibodies compare to Poolbeg Pharma?

Fusion Antibodies (LON:FAB) and Poolbeg Pharma (LON:POLB) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations, earnings and media sentiment.

Poolbeg Pharma has a net margin of 0.00% compared to Fusion Antibodies' net margin of -91.92%. Poolbeg Pharma's return on equity of -55.47% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Fusion Antibodies-91.92% -210.32% -63.78%
Poolbeg Pharma N/A -55.47%-21.33%

In the previous week, Poolbeg Pharma had 5 more articles in the media than Fusion Antibodies. MarketBeat recorded 5 mentions for Poolbeg Pharma and 0 mentions for Fusion Antibodies. Poolbeg Pharma's average media sentiment score of 0.01 beat Fusion Antibodies' score of 0.00 indicating that Poolbeg Pharma is being referred to more favorably in the news media.

Company Overall Sentiment
Fusion Antibodies Neutral
Poolbeg Pharma Neutral

7.6% of Fusion Antibodies shares are owned by institutional investors. Comparatively, 1.5% of Poolbeg Pharma shares are owned by institutional investors. 5.9% of Fusion Antibodies shares are owned by insiders. Comparatively, 7.5% of Poolbeg Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Fusion Antibodies has higher revenue and earnings than Poolbeg Pharma. Fusion Antibodies is trading at a lower price-to-earnings ratio than Poolbeg Pharma, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A
Poolbeg PharmaN/AN/A-£4.50B-£0.94N/A

Fusion Antibodies has a beta of 1.224, indicating that its share price is 22% more volatile than the broader market. Comparatively, Poolbeg Pharma has a beta of 1.812, indicating that its share price is 81% more volatile than the broader market.

Summary

Poolbeg Pharma beats Fusion Antibodies on 9 of the 12 factors compared between the two stocks.

How does Fusion Antibodies compare to hVIVO?

hVIVO (LON:HVO) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, analyst recommendations, earnings, media sentiment, profitability, valuation, risk and institutional ownership.

hVIVO has a net margin of -12.48% compared to Fusion Antibodies' net margin of -91.92%. hVIVO's return on equity of -14.65% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
hVIVO-12.48% -14.65% 11.97%
Fusion Antibodies -91.92%-210.32%-63.78%

In the previous week, hVIVO had 1 more articles in the media than Fusion Antibodies. MarketBeat recorded 1 mentions for hVIVO and 0 mentions for Fusion Antibodies. hVIVO's average media sentiment score of 1.27 beat Fusion Antibodies' score of 0.00 indicating that hVIVO is being referred to more favorably in the media.

Company Overall Sentiment
hVIVO Positive
Fusion Antibodies Neutral

hVIVO currently has a consensus target price of GBX 15, indicating a potential upside of 123.38%. Given hVIVO's stronger consensus rating and higher probable upside, equities research analysts clearly believe hVIVO is more favorable than Fusion Antibodies.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
hVIVO
0 Sell rating(s)
1 Hold rating(s)
2 Buy rating(s)
0 Strong Buy rating(s)
2.67
Fusion Antibodies
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
0.00

11.8% of hVIVO shares are owned by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are owned by institutional investors. 4.9% of hVIVO shares are owned by company insiders. Comparatively, 5.9% of Fusion Antibodies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

hVIVO has higher revenue and earnings than Fusion Antibodies. hVIVO is trading at a lower price-to-earnings ratio than Fusion Antibodies, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
hVIVO£46.77M0.99£17.84M-£0.87N/A
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A

hVIVO has a beta of 1.707, meaning that its stock price is 71% more volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, meaning that its stock price is 22% more volatile than the broader market.

Summary

hVIVO beats Fusion Antibodies on 13 of the 16 factors compared between the two stocks.

How does Fusion Antibodies compare to Roquefort Therapeutics?

Roquefort Therapeutics (LON:COIL) and Fusion Antibodies (LON:FAB) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their dividends, profitability, media sentiment, earnings, institutional ownership, risk, analyst recommendations and valuation.

Roquefort Therapeutics has higher earnings, but lower revenue than Fusion Antibodies. Fusion Antibodies is trading at a lower price-to-earnings ratio than Roquefort Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Roquefort TherapeuticsN/AN/A-£1.52M-£21.90N/A
Fusion Antibodies£1.60M8.47-£4.10M-£1.50N/A

2.1% of Roquefort Therapeutics shares are held by institutional investors. Comparatively, 7.6% of Fusion Antibodies shares are held by institutional investors. 36.1% of Roquefort Therapeutics shares are held by insiders. Comparatively, 5.9% of Fusion Antibodies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Fusion Antibodies has a net margin of -91.92% compared to Roquefort Therapeutics' net margin of -57,057.07%. Roquefort Therapeutics' return on equity of -18.71% beat Fusion Antibodies' return on equity.

Company Net Margins Return on Equity Return on Assets
Roquefort Therapeutics-57,057.07% -18.71% -15.86%
Fusion Antibodies -91.92%-210.32%-63.78%

Roquefort Therapeutics has a beta of 0.05, suggesting that its share price is 95% less volatile than the broader market. Comparatively, Fusion Antibodies has a beta of 1.224, suggesting that its share price is 22% more volatile than the broader market.

In the previous week, Roquefort Therapeutics' average media sentiment score of 0.00 equaled Fusion Antibodies'average media sentiment score.

Company Overall Sentiment
Roquefort Therapeutics Neutral
Fusion Antibodies Neutral

Summary

Roquefort Therapeutics and Fusion Antibodies tied by winning 5 of the 10 factors compared between the two stocks.

Get Fusion Antibodies News Delivered to You Automatically

Sign up to receive the latest news and ratings for FAB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FAB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FAB vs. The Competition

Export
MetricFusion AntibodiesBiotechnology IndustryMedical SectorLON Exchange
Market Cap£13.52M£521.79M£6.85B£2.78B
Dividend YieldN/A3.90%2.68%6.12%
P/E Ratio-7.203.4927.04368.21
Price / Sales8.476,415.64524.2584,742.79
Price / Cash9.0213.1348.5927.87
Price / Book3.0786.7010.807.52
Net Income-£4.10M-£96.07M£3.59B£5.89B
7 Day Performance0.62%-0.20%-1.46%0.83%
1 Month Performance-10.00%2.11%2.82%-1.30%
1 Year Performance54.51%61.47%28.59%62.41%

Fusion Antibodies Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FAB
Fusion Antibodies
N/AGBX 10.80
-1.8%		N/A+61.3%£13.52M£1.60MN/A48
HEMO
Hemogenyx Pharmaceuticals
N/AGBX 804.18
+4.4%		N/A+431.6%£54.68MN/AN/A14
ETX
e-therapeutics
N/AN/AN/AN/A£52.59M£295KN/A35
POLB
Poolbeg Pharma
N/AGBX 6.90
+0.7%		N/A+92.1%£48.65MN/AN/A12
HVO
hVIVO
2.8297 of 5 stars		GBX 6.96
flat		GBX 15
+115.7%		-33.4%£47.88M£46.77MN/AN/A

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (LON:FAB) was last updated on 7/15/2026 by MarketBeat.com Staff.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Trump Takes Emergency Action - Plus Elon Musk's New Venture
Elon Musk has quietly launched a new venture - one that has nothing to do with rockets, EVs, or Neuralink. Tru...
Altimetry | Sponsoredtc pixel
Your $29.97 book is free today
Why Some Traders Skip Stocks Entirely You don't need a big account to trade options. In fact, options ca...
Profits Run | Sponsoredtc pixel
SPCX Warning - and Worst News for Stocks in 50 Years
Goldman Sachs and Morgan Stanley are now predicting what could be the worst news for the U.S. stock market in ...
TradeSmith | Sponsoredtc pixel
CODE RED: AI Meltdown Imminent?
After correctly predicting the 2008 and 2020 stock market meltdowns, I believe this AI company is about to tri...
Paradigm Press | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
From the man who predicted 2008 crash…
Porter Stansberry, founder of one of the largest financial research firms in the world, says he's breaking the...
Porter & Company | Sponsoredtc pixel